Asociación entre sobrepeso/obesidad y tuberculosis multidrogoresistente

Jesus Peinado; Leonid Lecca; Judith Jiménez; Roger Calderón; Rosa Yataco; Mercedes Becerrra; Megan Murray

doi:10.17843/rpmesp.2023.401.12138

Authors

Jesus Peinado Socios en Salud Sucursal Perú, Lima, Perú. Escuela de Medicina, Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Perú. https://orcid.org/0000-0003-2015-3170
Leonid Lecca Socios en Salud Sucursal Perú, Lima, Perú https://orcid.org/0000-0003-1363-3985
Judith Jiménez Socios en Salud Sucursal Perú, Lima, Perú https://orcid.org/0000-0001-7633-8401
Roger Calderón Socios en Salud Sucursal Perú, Lima, Perú https://orcid.org/0000-0001-8932-0489
Rosa Yataco Socios en Salud Sucursal Perú, Lima, Perú https://orcid.org/0000-0002-4776-8733
Mercedes Becerrra Partners in Health, Boston, Estados Unidos https://orcid.org/0000-0001-8281-2712
Megan Murray Harvard Medical School, Boston, Estados Unidos https://orcid.org/0000-0003-0443-1986

DOI:

https://doi.org/10.17843/rpmesp.2023.401.12138

Keywords:

Tuberculosis, sobrepeso, obesidad, resistencia

Abstract

Objective. To evaluate the association between overweight/obesity and multidrug resistance in patients with and without a history of tuberculosis treatment. Materials and methods. Cross-sectional study of secondary data from a tuberculosis cohort, which included anthropometric and drug-sensitivity testing data at the baseline visit of patients with and without previous tuberculosis treatment. Results. We evaluated 3,734 new cases and 766 with a history of having received treatment for tuberculosis. Overweight/obesity was not associated with multidrug resistance in patients with a history of tuberculosis treatment, with a prevalence ratio of 0.97 and a 95% confidence interval of 0.68-1.38. Conclusions. Overweight/obesity is not associated with multidrug resistance in tuberculosis. Overweight/obesity is a dynamic process that may influence the relationship between the immune system and the metabolic system.

Downloads

Download data is not yet available.

Author Biographies

Leonid Lecca, Socios en Salud Sucursal Perú, Lima, Perú

Director General Socios En Salud sucursal Perú
Judith Jiménez, Socios en Salud Sucursal Perú, Lima, Perú

Enfermera, jefe del programa de tuberculosis
Roger Calderón, Socios en Salud Sucursal Perú, Lima, Perú

Biologo, Director del laboratorio SES
Rosa Yataco, Socios en Salud Sucursal Perú, Lima, Perú

Enfermera, Jefe de monitoreo programático
Mercedes Becerrra, Partners in Health, Boston, Estados Unidos

Investigadora Harvard Medical School
Megan Murray, Harvard Medical School, Boston, Estados Unidos

Investigadora Harvard Medical School

References

World Health Organization. Tuberculosis control: Global Tuberculosis Report 2021 [Internet]. Geneva; 2021 [citado el de de 2022].

Disponible en: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.

Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. doi: 10.1101/CSHPERSPECT.A017863.

World Health Organization. Global tuberculosis report 2018 [Internet]. Geneva; 2018 [citado el de de 2022]. Disponible en: https://www.who.int/publications/i/item/9789241565646.

Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, et al. MDR Tuberculosis — Critical Steps for Prevention and Control. N Engl J Med. 2010;363(11):1050-1058. doi: 10.1056/NEJMra0908076.

Asencios L, Quispe N, Mendoza-Ticona A, Elena Leo LV, Jave O. Vigilancia Nacional de la Resistencia a Medicamentos Antituberculosos,

Perú 2005-2006. Rev Peru Med Exp Salud Pública. 2009;26(3):278-287. doi: 10.17843/rpmesp.2009.263.1376.

Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367(10):931-6. doi: 10.1056/NEJMra1205429.

Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug

resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894. doi: 10.1136/bmj.l5894.

Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic

review. PLoS One. 2017;12(4):e0175925. doi: 10.1371/journal.pone.0175925.

Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD. Association between diabetes mellitus and multi-drug-resistant

tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev. 2018;7(1):161. doi: 10.1186/s13643-018-0828-0.

Menon S, Peñalvo JL. Actions Targeting the Double Burden of Malnutrition: A Scoping Review. Nutrients. 2019;12(1):81. doi: 10.3390/nu12010081.

Pajuelo Ramírez J. La obesidad en el Perú. An Fac Med. 2017;78(2):179-185 doi: 10.15381/anales.v78i2.13214.

Søndergaard L. Homology between the mammalian liver and the Drosophila fat body. Trends Genet. 1993;9(6):193. doi: 10.1016/0168-9525(93)90113-v.

Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, et al. Body mass index predictive of sputum culture conversion among MDRTB patients in Indonesia. Int J Tuberc Lung Dis. 2014;18(5):564-70. doi: 10.5588/ijtld.13.0602.

Li XX, Lu W, Zu RQ, Zhu LM, Yang HT, Chen C, et al. Comparing risk factors for primary multidrug-resistant tuberculosis and primary drug-susceptible tuberculosis in Jiangsu province, China: a matched-pairs case-control study. Am J Trop Med Hyg. 2015;92(2):280-285. doi: 10.4269/ajtmh.13-0717.

Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8(12):e82943. doi: 10.1371/journal.pone.0082943.

Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. 2020;11(1):1-12. doi: 10.4239/wjd.v11.i1.1.

Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215-31. doi: 10.2165/00003088-200039030-00004.

Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000.

Chang MJ, Chae JW, Yun HY, Lee JI, Choi HD, Kim J, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb). 2015;95(1):54-9. doi: 10.1016/j.tube.2014.10.013.

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546-51. doi: 10.1128/AAC.01550-06.

Huerta-García AP, Medellín-Garibay SE, Salazar-González RA, Ortiz-Álvarez A, Magaña-Aquino M, Rodríguez-Pinal CJ, et al. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis. Ther Drug Monit. 2019 Oct;41(5):648-656. doi: 10.1097/FTD.0000000000000631.

Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204(12):1951-9. doi: 10.1093/infdis/jir658.

Hall RG 2nd, Swancutt MA, Meek C, Leff RD, Gumbo T. Ethambutol pharmacokinetic variability is linked to body mass in overweight,

obese, and extremely obese people. Antimicrob Agents Chemother. 2012;56(3):1502-7. doi: 10.1128/AAC.05623-11.

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis

outcomes. J Infect Dis. 2013;208(9):1464-73. doi: 10.1093/infdis/jit352.

Song WM, Guo J, Xu TT, Li SJ, Liu JY, Tao NN. Association between body mass index and newly diagnosed drug-resistant pulmonary

tuberculosis in Shandong, China from 2004 to 2019. BMC Pulm Med. 2021;21(1):399. doi: 10.1186/s12890-021-01774-2.

Odone A, Calderon R, Becerra MC. Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants.

PLoS One. 2016;11(1):e0146642. doi: 10.1371/journal.pone.0146642.

Lin HH, Wu CY, Wang CH, Fu H, Lönnroth K, Chang YC, et al. Association of Obesity, Diabetes, and Risk of Tuberculosis: Two Population-Based Cohorts. Clin Infect Dis. 2018 Feb 10;66(5):699-705. doi: 10.1093/cid/cix852.

Yen YF, Hu HY, Lee YL, Ku PW, Lin IF, Chu D, et al. Obesity/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan. Int J Obes (Lond). 2017;41(6):971-975. doi: 10.1038/ijo.2017.64.

Kovalskys I, Fisberg M, Gómez G, Pareja RG, Yépez García MC, Cortés Sanabria LY, et al. Energy intake and food sources of eight

Latin American countries: results from the Latin American Study of Nutrition and Health (ELANS). Public Health Nutr. 2018;21(14):2535-

doi: 10.1017/S1368980018001222.

Woolcott OO, Gutierrez C, Castillo OA, Elashoff RM, Stefanovski D, Bergman RN. Inverse association between altitude and obesity: A prevalence study among andean and low-altitude adult individuals of Peru. Obesity (Silver Spring). 2016;24(4):929-37. doi: 10.1002/oby.21401.

Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with

previous treatment and HIV co-infection? Ethiop J Health Sci. 2013;23(3):271-82. doi: 10.4314/ejhs.v23i3.10.

Sultana ZZ, Hoque FU, Beyene J, Akhlak-Ul-Islam M, Khan MHR, Ahmed S, et al. HIV infection and multidrug resistant tuberculosis: a

systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):51. doi: 10.1186/s12879-020-05749-2.

Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. Prz Menopauzalny. 2017 Jun;16(2):38-43. doi: 10.5114/pm.2017.68589.

Chen X, Zhou T, Wang D. The Impact of Multidimensional Health Levels on Rural Poverty: Evidence from Rural China. Int J Environ

Res Public Health. 2022;19(7):4065. doi: 10.3390/ijerph19074065.

Instituto Nacional de Estadística e Informática. Informe técnico, evolución de la pobreza 2007-2011 [Internet]. INEI: Perú; 2012 [citado el de de 2022]. Disponible en: https://www.inei.gob.pe/media/cifras_de_pobreza/pobreza_informetecnico.pdf.